Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 208, Issue 6, Pages 892-897Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jit280
Keywords
HIV; enfuvirtide; raltegravir; IL-6; CRP; D-dimer; switch; biomarkers
Categories
Funding
- ANRS
- Merck
- Centre d'Etudes et de Recherches en Infectiologie
Ask authors/readers for more resources
Stored plasma specimens from 164 participants in the ANRS 138 trial were analyzed to determine interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP), and D-dimer levels at baseline and weeks 24 and 48. These virologically suppressed, treatment-experienced patients were randomly assigned to undergo an immediate switch (IS) or a deferred switch (DS; at week 24) from an enfuvirtide-based antiretroviral therapy (ART) regimen to a raltegravir-based regimen. At week 24, a significant decrease from baseline was observed in the IS arm, compared with the DS arm, for IL-6 level (-30% vs +10%; P < .002), hsCRP level (-46% vs +15%; P < .0001), and D-dimer level (-40% vs +6%; P < .0001). At week 48, there was a reproducible decrease in levels of all biomarkers in the DS arm.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available